Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07189065 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Sep 30, 2025 to Nov 27, 2025 · Site details revised at 41 of 41 sitesv2 Show 2 more changesShow less
    • Start date changed from estimate of Sep 30, 2025 to Nov 27, 2025
    • Site details revised at 41 of 41 sites
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is an open-label, randomized controlled, multicenter Phase II clinical study primarily evaluating the efficacy and safety of Rocbrutinib monotherapy compared to the investigator's choice of BR/R2 regimen in patients with non-GCB DLBCL.
Trial Details
NCT Number NCT07189065
Lead Sponsor Guangzhou Lupeng Pharmaceutical Company LTD.
Conditions Diffuse Large B-Cell Lymphoma (DLBCL)
Enrollment 150 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov